AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of “Moderate Buy” by Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has been given an average recommendation of “Moderate Buy” by the eleven brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $66.8889.

ANAB has been the topic of a number of analyst reports. Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. HC Wainwright dropped their target price on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a report on Monday, November 24th. Stifel Nicolaus decreased their price target on AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Barclays lifted their price objective on AnaptysBio from $55.00 to $78.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, January 21st.

AnaptysBio Stock Up 0.4%

NASDAQ ANAB opened at $49.95 on Tuesday. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -17.71 and a beta of 0.35. AnaptysBio has a twelve month low of $12.21 and a twelve month high of $52.47. The business’s fifty day moving average is $47.03 and its 200 day moving average is $34.97.

AnaptysBio declared that its board has authorized a share repurchase program on Friday, November 21st that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the biotechnology company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its shares are undervalued.

Insider Transactions at AnaptysBio

In other news, Director Magda Marquet sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $48.23, for a total value of $530,530.00. Following the transaction, the director owned 9,930 shares in the company, valued at $478,923.90. This trade represents a 52.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Paul F. Lizzul sold 3,650 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $44.71, for a total value of $163,191.50. Following the completion of the sale, the insider directly owned 42,088 shares of the company’s stock, valued at $1,881,754.48. The trade was a 7.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 146,280 shares of company stock valued at $6,714,939. Company insiders own 33.50% of the company’s stock.

Institutional Trading of AnaptysBio

Hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of AnaptysBio by 24.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 263 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of AnaptysBio by 21.2% during the fourth quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 284 shares in the last quarter. Bessemer Group Inc. increased its position in shares of AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares during the last quarter. Corton Capital Inc. raised its stake in AnaptysBio by 12.2% in the second quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 1,305 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,377 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.